Real-world predictors of survival in patients with extensive-stage small-cell lung cancer in Manitoba, Canada: a retrospective cohort study

Real-world predictors of survival in patients with extensive-stage small-cell lung cancer in Manitoba, Canada: a retrospective cohort study

BackgroundExtensive-stage small-cell lung cancer (ES-SCLC) is an incurable cancer with poor prognosis in which characteristics predictive of long-term survival are debated. The utility of agents such as immune checkpoint inhibitors highlights the importance of identifying key characteristics and tre...

Full description

Bibliographic Details
Main Authors:	David E. Dawe, Rebekah Rittberg, Iqra Syed, Mary Kate Shanahan, Daniel Moldaver, Oliver Bucher, Katie Galloway, Kayla Reynolds, James T. Paul, Craig Harlos, Julian O. Kim, Shantanu Banerji
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-09-01
Series:	Frontiers in Oncology
Subjects:	radiotherapy (RT) small cell lung cancer (SCLC) extensive stage (ES) performance status (ECOG-PS) real world long-term survival
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1191855/full

Similar Items

Real-world predictors of survival in patients with limited-stage small-cell lung cancer in Manitoba, Canada
by: David E. Dawe, et al.
Published: (2023-12-01)

The Role of Immunotherapy in the Treatment of Malignant Pleural Mesothelioma
by: Shantanu Banerji, et al.
Published: (2021-11-01)

Real-world eligibility for platinum doublet plus immune checkpoint inhibitors in extensive-stage small-cell lung cancer
by: Rebekah Rittberg, et al.
Published: (2022-09-01)

Real World Patient Eligibility for Second Line Lurbinectedin Based Treatment in Small Cell Lung Cancer: Understanding Epidemiology and Estimating Health Care Utilization
by: Rebekah Rittberg, et al.
Published: (2022-12-01)

Prognostic value of systemic inflammation and for patients with colorectal cancer cachexia
by: Guo‐Tian Ruan, et al.
Published: (2023-12-01)

The relationship between clinicopathological variables, systemic inflammation, and CT‐derived body composition with survival in patients with advanced non‐small cell lung cancer receiving nivolumab as a second‐line treatment
by: Randa Saeed, et al.
Published: (2023-12-01)

A Natural Language Processing Algorithm to Improve Completeness of ECOG Performance Status in Real-World Data
by: Aaron B. Cohen, et al.
Published: (2023-05-01)

Ramucirumab in Indian Patients with Advanced Gastric Cancer—Does Borderline Performance Status and Heavy Burden of Disease in Real World Practice Impact Clinical Benefit?
by: Anant Ramaswamy, et al.
Published: (2022-01-01)

Impact of Performance Status on Survival Outcomes and Health Care Utilization in Patients With Advanced NSCLC Treated With Immune Checkpoint Inhibitors
by: Daniel E. Meyers, MD, MSc, et al.
Published: (2023-04-01)

Survival Analysis of Advanced Lung Cancer: Examining Factors Impacting Mortality Risk
by: Paul Poku Sampene OSSEI, et al.
Published: (2023-09-01)

Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study
by: Valerio Gristina, et al.
Published: (2022-12-01)

Reliability of prehospital patient classification in helicopter emergency medical service missions
by: A. Heino, et al.
Published: (2020-05-01)

Data-driven identification of plasma metabolite clusters and metabolites of interest for potential detection of early-stage non-small cell lung cancer cases versus cancer-free controls
by: Julian O. Kim, et al.
Published: (2022-10-01)

Immune Checkpoint Inhibition as Primary Adjuvant Therapy for an <i>IDH1</i>-Mutant Anaplastic Astrocytoma in a Patient with CMMRD: A Case Report—Usage of Immune Checkpoint Inhibition in CMMRD
by: Rebekah Rittberg, et al.
Published: (2021-02-01)

Physician-reported ECOG-PS versus patient-reported (self) ECOG-PS: Which one is a better predictor of survival in cancer?
by: Arif Hakan Onder, et al.
Published: (2023-09-01)

Real-World Data of Combined Immunochemotherapy in Patients With Nonsquamous Advanced NSCLC. A Single-Center Retrospective Study
by: Till Wallrabenstein, MD, et al.
Published: (2023-05-01)

Tracheal polypoid combined small cell lung cancer (C‐SCLC): A case report
by: Alberto Testori, et al.
Published: (2021-07-01)

Pathology and Classification of SCLC
by: Maria Gabriela Raso, et al.
Published: (2021-02-01)

Influence of Performance Status on the Effectiveness of Pembrolizumab Monotherapy in First-Line for Advanced Non-Small-Cell Lung Cancer: Results in a Real-World Population
by: Rocío Jiménez Galán, et al.
Published: (2021-09-01)

Stereotactic Body Radiotherapy (SBRT) in Very Limited-Stage Small Cell Lung Cancer (VLS-SCLC)
by: Stéphanie L. Mercier, et al.
Published: (2022-12-01)

Molecular Subtypes of High-Grade Neuroendocrine Carcinoma (HGNEC): What is YAP1-Positive HGNEC?
by: Hitomi Kawai, et al.
Published: (2022-03-01)

A Review of Recent Advances in the Treatment of Elderly and Poor Performance NSCLC
by: Juliet A. Carmichael, et al.
Published: (2018-07-01)

Treatment of Metastatic Disease with Immune Checkpoint Inhibitors Nivolumab and Pembrolizumab: Effect of Performance Status on Clinical Outcomes
by: Leah Wells, et al.
Published: (2022-05-01)

Clinicopathological Difference and Survival Impact of Patients with c-SCLC and SCLC
by: Zhang C, et al.
Published: (2021-10-01)

Comparative metabolomics studies of blood collected in streck and heparin tubes from lung cancer patients.
by: Erin Goldberg, et al.
Published: (2021-01-01)

Altered dynamical integration/segregation balance during anesthesia-induced loss of consciousness
by: Louis-David Lord, et al.
Published: (2023-12-01)

Canadian Cancer Centre Response to COVID-19 Pandemic: A National and Provincial Response
by: Rebekah Rittberg, et al.
Published: (2020-12-01)

Neuroendocrine Tumors of the Lung
by: Melanie Demes, et al.
Published: (2012-07-01)

Small cell lung cancer transformation during antitumor therapies: A systematic review
by: Chai Xing, et al.
Published: (2021-08-01)

Intrasulcal electrocorticography in macaque monkeys with minimally invasive neurosurgical protocols
by: Takeshi eMatsuo, et al.
Published: (2011-05-01)

Adaptive brain shut-down counteracts neuroinflammation in the near-term ovine fetus
by: Alex eXU, et al.
Published: (2014-06-01)

Development of a bending test procedure for the characterization of flexible ECoG electrode arrays
by: Kohler Fabian, et al.
Published: (2015-09-01)

Propofol, An Alternative to Amobarbital in Wadas Test in Electro corticography Based Epilepsy Surgery for Determining Dominance of Brain
by: Pravesh Rajbhandari, et al.
Published: (2016-12-01)

Distributed Subnetworks of Depression Defined by Direct Intracranial Neurophysiology
by: Katherine Wilson Scangos, et al.
Published: (2021-10-01)

Real world risk of infusion reactions and effectiveness of front-line obinutuzumab plus chlorambucil compared with other frontline treatments for chronic lymphocytic leukemia
by: Nicole Bourrier, et al.
Published: (2022-02-01)

Early beta oscillations in multisensory association areas underlie crossmodal performance enhancement
by: Georgios Michail, et al.
Published: (2022-08-01)

New therapies in small cell lung cancer: A narrative review
by: Sotirios Papavasileiou, et al.
Published: (2024-03-01)

The prognostic value of pretreatment albumin-to-fibrinogen ratio in small cell lung cancer patients receiving first-line platinum-based chemotherapy
by: Qi Li, et al.
Published: (2023-09-01)

Advanced Lung Cancer Inflammation Index is a Prognostic Factor of Patients with Small-Cell Lung Cancer Following Surgical Resection
by: Hu Z, et al.
Published: (2021-02-01)

Value of pretreatment serum lactate dehydrogenase as a prognostic and predictive factor for small‐cell lung cancer patients treated with first‐line platinum‐containing chemotherapy
by: Man He, et al.
Published: (2021-12-01)